Regulatory Mechanisms of Vav Family GTP Exchange Factors in Cancer

The Vav family of guanine nucleotide exchange factors (GEFs) comprises three paralogues—Vav1, Vav2 and Vav3—that catalyse the activation of Rho GTPases and act as scaffolds downstream of protein tyrosine kinases. In healthy tissues, their catalytic activity is tightly controlled by intramolecular interactions and tyrosine phosphorylation; in cancer, these layers of regulation are frequently subverted by overexpression, mutation or aberrant upstream signalling. Dysregulated Vav proteins drive oncogenic programmes by promoting cytoskeletal remodelling, mitogenic and survival pathways, transcriptional networks mediated by c-Myc and YAP/TAZ, and alterations in ribosome biogenesis. The balance between their catalytic and non-catalytic functions further determines whether a given tumour type exhibits enhanced proliferation, altered differentiation or, paradoxically, suppression of malignant transformation. Understanding these regulatory mechanisms has revealed new vulnerabilities—such as RNA polymerase I dependence in high-Vav2 contexts—and has highlighted the importance of co-operating genetic lesions for full tumourigenic potential.

Research from Nature Portfolio

Recent studies have delineated how Vav2 orchestrates regenerative proliferation and metabolic adaptation in squamous cell carcinomas. One report demonstrated that Vav2 drives both keratinocyte proliferation and oral squamous cell carcinoma progression by engaging RAC1 and RHOA through PAK and ROCK kinases, thereby activating c-Myc and YAP/TAZ-dependent transcriptional programmes associated with poor differentiation. A follow-up investigation uncovered that Vav2 also governs ribosome biogenesis in these cells: by promoting RNA polymerase I activity and upregulating ribosomal assembly factors, Vav2 establishes a heightened demand for ribogenesis that can be therapeutically targeted via inhibition of RNA polymerase I. Earlier work revealed that Vav2 is both necessary and sufficient to induce a regenerative-like state in head and neck keratinocytes by means of a catalysis-dependent mechanism, with elevated Vav2 transcript levels and downstream signatures correlating with adverse patient prognosis.

Regulatory Mechanisms of Vav Family GTP Exchange Factors in Cancer publication trend

The graph below shows the total number of articles in regulatory mechanisms of vav family gtp exchange factors in cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Guanine nucleotide exchange factor (GEF): Protein that catalyses the exchange of GDP for GTP on small GTPases, thereby activating them.

Rho GTPases: A family of small signalling G proteins (including RhoA, Rac1 and Cdc42) that regulate cytoskeletal dynamics, gene transcription and cell proliferation.

Tyrosine phosphorylation: Addition of a phosphate group to a tyrosine residue on a protein, often triggering conformational changes and activation of signalling pathways.

Autocrine/paracrine signalling: Modes of cell communication where cells secrete factors that act on themselves (autocrine) or neighbouring cells (paracrine) to regulate proliferation and inflammation.

Ribosome biogenesis: The multistep process of synthesising and assembling ribosomal RNA and proteins into functional ribosomes, essential for protein synthesis and cell growth.

References

1. The Vav GEF Family: An Evolutionary and Functional Perspective. Cells (2019).
2. VAV2 signaling promotes regenerative proliferation in both cutaneous and head and neck squamous cell carcinoma. Nature Communications (2020).
3. VAV2 orchestrates the interplay between regenerative proliferation and ribogenesis in both keratinocytes and oral squamous cell carcinoma. Scientific Reports (2024).
4. Unraveling the Oncogenic Potential of VAV1 in Human Cancer: Lessons from Mouse Models. Cells (2023).
5. The Rho Exchange Factors Vav2 and Vav3 Favor Skin Tumor Initiation and Promotion by Engaging Extracellular Signaling Loops. PLOS Biology (2013).
6. A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia. Cancer Cell (2017).